LEADER 03634nam  22006975  450 
001 9910298314303321
005 20200704123920.0
010   $a94-017-8035-8
024 7 $a10.1007/978-94-017-8035-3
035   $a(CKB)3710000000084238
035   $a(EBL)1636844
035   $a(OCoLC)871044368
035   $a(SSID)ssj0001152608
035   $a(PQKBManifestationID)11682032
035   $a(PQKBTitleCode)TC0001152608
035   $a(PQKBWorkID)11149429
035   $a(PQKB)11262650
035   $a(MiAaPQ)EBC1636844
035   $a(DE-He213)978-94-017-8035-3
035   $a(PPN)176130608
035   $a(EXLCZ)993710000000084238
100   $a20140106d2014      u|             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aAngiogenesis and Anti-Angiogenesis in Hematological Malignancies$b[electronic resource] /$fby Domenico Ribatti
205   $a1st ed. 2014.
210  1$aDordrecht :$cSpringer Netherlands :$cImprint: Springer,$d2014.
215   $a1 online resource (118 p.)
300   $aDescription based upon print version of record.
311   $a94-017-8034-X 
320   $aIncludes bibliographical references and index.
327   $aPreface -- Introduction -- Angiogenesis in multiple myeloma -- Angiogenesis in lymphomas -- Angiogenesis in leukemia -- Antiangiogenesis -- Concluding remarks -- References.
330   $aIt has been generally accepted that angiogenesis is involved in the pathogenesis of hematological malignancies, like acute and chronic leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms and multiple myeloma. The extent of angiogenesis in the bone marrow has been correlated with disease burden, prognosis and treatment outcome. Reciprocal positive and negative interactions between tumor cells and bone marrow stromal cells, namely hematopoietic stem cells, fibroblasts, osteoblasts/osteoclasts, endothelial cells, endothelial progenitor cells, T cells, macrophages and mast cells, mediated by an array of cytokines, receptors and adhesion molecules, modulate the angiogenic response in hematological tumors. More recently, it has been emphasized the pro-angiogenic role of the so called ?vascular niche?, indicating a site rich in blood vessels where endothelial cells and mural cells such as pericytes and smooth muscle cells create a microenvironment that affects the behavior of several stem and progenitor cells, in hematological malignancies.
606   $aCancer research
606   $aOncology  
606   $aHematology
606   $aLife sciences
606   $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001
606   $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160
606   $aHematology$3https://scigraph.springernature.com/ontologies/product-market-codes/H3307X
606   $aLife Sciences, general$3https://scigraph.springernature.com/ontologies/product-market-codes/L00004
615  0$aCancer research.
615  0$aOncology  .
615  0$aHematology.
615  0$aLife sciences.
615 14$aCancer Research.
615 24$aOncology.
615 24$aHematology.
615 24$aLife Sciences, general.
676   $a570
676   $a599.017
676   $a599/.017
700   $aRibatti$b Domenico$4aut$4http://id.loc.gov/vocabulary/relators/aut$0793065
712 02$aEuropean Union.
906   $aBOOK
912   $a9910298314303321
996   $aAngiogenesis and Anti-Angiogenesis in Hematological Malignancies$92502661
997   $aUNINA